BHV-1320

BHV-1320 is an investigational extracellular protein degrader developed by Biohaven using its proprietary Molecular Degrader of Extracellular proteins (MoDE) platform. The therapy is a bifunctional molecule designed to selectively bind to Immunoglobulin G (IgG) and the asialoglycoprotein receptor (ASGPR) on the surface of hepatocytes. This recruitment facilitates the internalization and subsequent lysosomal degradation of circulating IgG, thereby reducing the levels of pathogenic autoantibodies. BHV-1320 is specifically engineered for subcutaneous administration, distinguishing it from the lead intravenous candidate BHV-1300, and is intended to provide a more patient-friendly maintenance therapy for chronic autoantibody-mediated autoimmune diseases such as Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Graves' disease.

Other names

IgG MoDE (Subcutaneous)